SPOTLIGHT -
Post-surgery nivolumab boosts disease-free survival in muscle-invasive urothelial carcinoma
Adjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.